SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luis a. garcia who wrote (415)8/16/1997 8:12:00 PM
From: John Zwiener   of 1115
 
I compared other similar companies (more or less) with positive phase 3 results, but not approved. They seem to have market caps of around 400-500 million. But it's hard to compare expected revenues (total potential market sales, percentage of patent owned, royalties, if they manufacture the drug themselves, etc). I think that Lidak would compare favoribly to these other companies, but basically, Lidak may be worth 4 or 5 times the current price. I think we will see this stock valued 12 to 15 dollars based on Thursdays info. If it gets approved, then around 20-30 dollars. After sales get started, then price could go to 50-75 if expectations ar met.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News